
Quarterly ResultAug 3, 2026, 06:41 AM
Boston Scientific Q2 Net Sales $5.44B, EPS $0.61; Penumbra Acquisition Update
AI Summary
Boston Scientific reported strong financial results for Q2 2026, with net sales increasing 7.5% to $5.44 billion and diluted EPS rising 15.1% to $0.61. The company also provided updates on significant strategic activities, including the pending $14.5 billion acquisition of Penumbra and a $1.5 billion investment in MiRus LLC. Additionally, Boston Scientific completed the acquisition of Nalu Medical for $523 million during the quarter.
Key Highlights
- Agreed to acquire Penumbra for approximately $14.5 billion, pending regulatory clearance.
- Invested $1.5 billion in MiRus LLC for 33.75% equity and an option to acquire its TAVR business.
- Completed Nalu Medical acquisition for $523 million, integrating into Neuromodulation.
- Q2 2026 Net Sales increased 7.5% to $5.44 billion from $5.06 billion year-over-year.
- Q2 2026 Diluted EPS rose 15.1% to $0.61 from $0.53 year-over-year.
- Q2 2026 Net Income attributable to common stockholders grew 13.8% to $907 million.
- Q2 2026 Operating Income increased 43.8% to $1.18 billion.
Price Impact
More from BSX